oncosec medical inc (ONCS) Key Developments
Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms
Feb 18 15
Heat Biologics, Inc. and OncoSec Medical Inc. announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. Under the agreement, Heat and OncoSec will jointly evaluate the preclinical efficacy of Heat's proprietary gp-96-Ig based ImPACT immunotherapy platform using OncoSec's core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform. Heat and OncoSec are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110 ) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410 ) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer. OncoSec's core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma.
OncoSec Medical Incorporated and ARE-SD Region No. 18, LLC Enter into Lease Agreement for Corporate Headquarters and Research and Development Laboratory
Jan 2 15
On December 31, 2014, OncoSec Medical Incorporated (the Company) and ARE-SD Region No. 18, LLC (the Landlord) entered into a Lease Agreement (the Lease Agreement). Pursuant to the Lease Agreement, the Company has leased certain premises of approximately 33,928 rentable square feet located at 5820 Nancy Ridge Drive, San Diego, California to serve as the company's corporate headquarters and research and development laboratory. The term of the lease agreement is expected to commence on or about October 1, 2015 (the Commencement Date), and expires one hundred twenty (120) months after the Commencement Date.
OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM
Dec 15 14
OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.
Oncosec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse
Dec 9 14
OncoSec Medical Inc. has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment. The study will enroll patients with treatment-refractory metastatic and unresectable SCCHN, regardless of HPV status. Eligible patients will receive up to nine cycles of IL-12 ImmunoPulse at six-week intervals and will be followed for clinical response and safety. The first stage of the study will enroll 20 patients with measurable disease. If three or more objective responses are observed, an additional 11 patients with measurable disease will be treated, for a total of 31 patients. The primary endpoint for this study will be best overall response by RECIST 1.1.
Oncosec Medical Inc. Announces Earnings Results for the First Quarter Ended October 31, 2014
Dec 8 14
OncoSec Medical Inc. announced earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.